FDA’s advisory group approved reformulated tri-valent COVID-19 booster shots with no testing needed.

On June 28, 2022, the FDA's advisory body, VRBPAC, met and voted 19 to 2 to move forward with the next wave of COVID-19 booster shots to include a component that targets the Omicron variant.  The tri-valent boosters will be formulated with the obsolete Wuhan strain plus the BA.4 and BA.5 Omicron variants, even though there is little data. [2, 3] The urgency of this matter was pushed because vaccine manufactures wanted a vaccine strain selection by June 2022 in order to deliver shots for autumn/fall supply. On Saturday June 25, 2022, the FDA released their "strain selecting guidelines", the proposed "Future Framework" for addressing future COVID-19 vaccine strain composition. [1]  The FDA will not require clinical trials for these strain changes! The briefing document states: “The evaluation of modified vaccines for the purpose of vaccine strain composition decisions will need to rely mainly on comparative immunogenicity data due to the time constraints involved in vaccine manufacturing and clinical efficacy evaluation.” Skipping clinical trials all together.  The FDA assume the vaccines are safe (even though they are still emergency use), and with regards to effective, they will determine this simply through achieving an antibody response! WATCH

FDA introduces “Future Framework” for re-coding mRNA vaccines, no need for trials!

The FDA's advisory group VRBPAC discussed the "Future Framework" for the first time on April 6, 2022.  "All of the committee members agreed that COVID-19 shots are not working, that boosting multiple times a year was not feasible, and that the shots need to be reformulated. They also unanimously agreed that there are no “correlates of protection” that one can use to predict what antibody levels would be sufficient to prevent SARS-CoV-2 infection." The “Future Framework” is a plan to rig the Covid-19 vaccine regulatory process in perpetuity with the so-called “next generation” COVID-19 shots. The urgency of this matter was pushed because vaccine manufactures wanted a vaccine strain selection by June 2022 in order to deliver shots for autumn supply. On June 28, 2022, VRBPAC met and voted to move forward with boosters formulated with Wuhan and Omicron variants even though there is little data. [2]

WHO extends PHEIC and reinforces “COVID-19 is nowhere near over”

At the World Health Organisation (WHO) press briefing on July 12, 2022, the Director General stated [1] "Sub-variants of Omicron, like BA.4 and BA.5, continue to drive waves of cases, hospitalization and death around the world..." and the "[n]ew waves of the virus demonstrate again that the COVID-19 is nowhere near over" He announced that the Emergency Committee on COVID-19 met on Friday July 8, 2022 and extended the Public Health Emergency of International Concern (PHEIC) because: Waves of cases, hospitalisation and death around the world from sub-variant BA.4 and BA.5 Testing and sequencing surveillance has reduced significantly Diagnostics, treatments and vaccines are not being deployed effectively There is a major disconnect in COVID-19 risk perception "New waves of the virus demonstrate again that the COVID-19 is nowhere near over" "We have safe and effective tools that prevent infections, hospitalizations and deaths." "As transmission and hospitalisations rise, governments must also deploy tried and tested measures like masking, improved ventilation and test and treat protocols" Tedros also promoted other vaccinations, including new ones.  "Today, WHO released the first-ever report on vaccines in development to prevent infections caused by antimicrobial resistant bacterial pathogens." The vaccine were meant to render the pandemic over,..> READ MORE
Dr James A Thorp
Posted inCredentialed Experts

Dr James Thorp

Dr James Thorp is an extensively published 68-year-old physician MD from Florida, he is board-certified in obstetrics and gynecology (OB/GYN) as well as a specialist in maternal-fetal medicine, who has practiced obstetrics for over 42 years. In his practice he…
13 July 2022Posted inCredentialed Experts

Beijing prevent WIV sharing virus isolates with Uni Texas

On January 24, 2020 it is reported in a Five Eyes intelligence report that officials in Beijing, China prevented the Wuhan Institute of Virology (WIV) from sharing virus sample isolates with the University of Texas. [There is a standing agreement between the labs] "The Galveston National Laboratory is a national biocontainment laboratory built at the University of Texas Medical Branch [UTMB] by the National Institutes of Health and the State of Texas to help combat global health threats" [1, 2] The UTMB released a statement in April 2020 saying the Galveston National Laboratory “has hosted Chinese scientists for training to work in the high-containment lab” and that its lab “is part of National Institute of Allergy and Infectious Diseases [NIAID] Biodefense Laboratory Network.” "According to the U.S. Education Department, the UT system reported 10 contracts with Huawei and 24 contracts with Chinese state-owned universities between 2014 and 2019, totaling nearly $13 million"

CDC withdraws EUA for it’s PCR test

On July 21, 2021, the CDC announce they will withdraw their request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel effective December 31, 2021.  This test was first introduced in February 2020 for detection of SARS-CoV-2 only. This PCR test was used to diagnose COVID-19 "cases" in 2020, justifying the need for a vaccine. [1] A month earlier in May 2021 a FOIA revealed that the CDC's PCR tests were “poorly designed and came with erroneous instructions that made it doubly difficult for labs to rely on the test’s results” and the CDC lab scientists knew that the tests failed 33% of the time yet didn’t stop it’s release.